Get the Stockscreener App
1.35
3.85%
0.05
Telomir Pharmaceuticals Inc stock is traded at $1.35, with a volume of 381.13K.
It is up +3.85% in the last 24 hours and down -17.68% over the past month.
Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.
See More
Previous Close:
$1.30
Open:
$1.3
24h Volume:
381.13K
Relative Volume:
0.14
Market Cap:
$43.58M
Revenue:
-
Net Income/Loss:
$-16.14M
P/E Ratio:
-2.50
EPS:
-0.54
Net Cash Flow:
$-3.99M
1W Performance:
+3.05%
1M Performance:
-17.68%
6M Performance:
-49.25%
1Y Performance:
-65.91%
1-Day Range:
$1.2747
$1.38
1-Week Range:
$1.2747
$1.4655
52-Week Range:
$1.12
$7.0791
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
Name
Telomir Pharmaceuticals Inc
Sector
Industry
Phone
786-396-6723
Address
100 SE 2ND ST, MIAMI
Compare TELO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
1.35 | 43.98M | 0 | -16.14M | -3.99M | -0.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-21-25 | Initiated | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc Stock (TELO) Latest News
Telomir Pharmaceuticals Inc. (TELO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will Telomir Pharmaceuticals Inc. bounce back from current supportMarket Performance Recap & Risk Controlled Stock Alerts - newser.com
Has Telomir Pharmaceuticals Inc. found a price floorPortfolio Return Report & Stepwise Swing Trade Plans - newser.com
Sentiment analysis tools applied to Telomir Pharmaceuticals Inc.2025 Dividend Review & Reliable Breakout Stock Forecasts - newser.com
How Telomir Pharmaceuticals Inc. stock reacts to global recession fearsQuarterly Investment Review & Long-Term Safe Return Strategies - newser.com
Analyzing Telomir Pharmaceuticals Inc. with risk reward ratio chartsWeekly Stock Report & High Return Trade Guides - newser.com
Momentum divergence signals in Telomir Pharmaceuticals Inc. chartJuly 2025 PostEarnings & Weekly Top Gainers Trade List - newser.com
Will Telomir Pharmaceuticals Inc. rebound enough to break evenMarket Volume Report & Safe Entry Point Alerts - newser.com
Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line - ACCESS Newswire
Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Re - The Marion Star
Telomir Pharmaceuticals (NASDAQ: TELO): Telomir-1 beats DFO in live-cell iron reduction - Stock Titan
Telomir Pharmaceuticals Unveils Promising Preclinical Data - TipRanks
Telomir Pharmaceuticals enters into stock purchase agreement - MSN
What’s the recovery path for long term holders of Telomir Pharmaceuticals Inc.July 2025 Setups & Trade Opportunity Analysis Reports - newser.com
Forecasting Telomir Pharmaceuticals Inc. price range with options dataRate Hike & Weekly Setup with ROI Potential - newser.com
What technical models suggest about Telomir Pharmaceuticals Inc.’s comebackJuly 2025 Breakouts & AI Driven Stock Price Forecasts - newser.com
What insider trading reveals about Telomir Pharmaceuticals Inc. stockEarnings Growth Report & Expert-Curated Trade Recommendations - newser.com
Telomir Pharmaceuticals Inc expected to post a loss of 7 cents a shareEarnings Preview - TradingView
Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells - The Daily News Journal
Telomir Pharmaceuticals Inc Stock (TELO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):